EU vs US: Which Medtech Launch Market Offers Best Returns?
This article was originally published in Clinica
Executive Summary
The global regulatory environment is both dynamic and fluid as different countries systems evolve to meet ever changing technological demands and to reflect experience gained. Throughout the history of the EU’s Medical Device Directives, the US has been perceived to be a tougher market to crack than the EU from the regulatory standpoint. However, this position may no longer be so clear-cut. Amanda Maxwell spoke with experienced medtech investor, Thierry Chignon, who views the US to be more attractive than it has been ever before.